首页|基于miRNA126调控PI3K/AKT/mTOR通路研究肾衰泄浊汤对大鼠主动脉VEC细胞的保护机制

基于miRNA126调控PI3K/AKT/mTOR通路研究肾衰泄浊汤对大鼠主动脉VEC细胞的保护机制

扫码查看
目的 基于miRNA126调控PI3K/AKT/mTOR通路从细胞、分子层面探究肾衰泄浊汤保护血管内皮细胞(Vascular Endothelial Cell,VEC),延缓慢性肾脏病合并动脉粥样硬化的作用机制。方法 制备大鼠慢性肾脏病合并动脉粥样硬化模型,50只造模成功的SD大鼠随机分为模型组、氯沙坦组、肾衰泄浊汤低、中、高剂量组,每组10只;另取10只大鼠为假手术组。各组相应给药处理8周后处死。分离血清制备空白对照组、模型组、氯沙坦组、肾衰泄浊汤低、中、高剂量组含药血清干预大鼠主动脉VEC细胞。用光镜、Hoechst 33258染色观察细胞形态;流式细胞仪检测各组细胞增殖与凋亡水平;qPCR、WB检测miRNA126调控PI3K/AKT/mTOR通路mRNA和蛋白的表达水平。结果 细胞培养后形态观察显示,与空白对照组相比,模型组出现较多漂浮细胞,各给药组较模型组细胞形态有改善,其中肾衰泄浊汤中剂量组表现较佳;与空白对照组相比,模型组细胞的增殖活性显著降低(P<0。01),细胞凋亡水平显著增高(P<0。01),各给药组细胞增殖与凋亡水平较模型组均有改善;与空白对照组大鼠VEC细胞相比,模型组miRNA126 mRNA的表达量明显下降(P<0。05),PI3K、AKT、mTOR基因与蛋白表达水平明显上升(P<0。05);与模型组相比,氯沙坦组和肾衰泄浊汤低、中、高剂量组miRNA126 mRNA的表达量明显上升(P<0。05),肾衰泄浊汤各组PI3K、AKT、mTOR基因与磷酸化蛋白表达水平下降(P<0。05),自噬相关Bcelin1蛋白表达水平上升(P<0。05)。结论 肾衰泄浊汤可能通过miRNA126调控PI3K/AKT/mTOR通路促进细胞自噬途径,维持主动脉VEC细胞稳态,发挥保护VEC,延缓慢性肾脏病合并动脉粥样硬化的作用。
Study on the protective mechanism of Shenshuai Xiezhou decoction on rat aortic VEC cells based on miRNA126 regulation of PI3K/AKT/mTOR pathway
Objective Based on miRNA126 regulating PI3K/AKT/mTOR pathway,we investigated the mechanism of Vascular Endothe-lial Cell(VEC)protection by Shenshuaixiezhuo Decoction at cellular and molecular levels to delay atherosclerosis in Chronic Kidney Dis-ease(CKD).Methods A rat model of chronic kidney disease combined with atherosclerosis was prepared,and 50 SD rats were random-ly divided into the model group,the chlorthalidomide group,and the low,medium and high dose groups of Shenshuaixiezhuo Decoction,with 10 rats in each group,and another 10 rats were taken as the sham-operation group.Each group was treated with the corresponding drugs for 8 weeks and then executed.Separate serum was prepared from the blank control group,model group,cloxacillin group,and low,medium and high dose groups of Shenshuaixiezhuo Decoction to intervene in the VEC cells of rat aorta.The cell morphology was ob-served by light microscopy and Hoechst 33258 staining;the proliferation and apoptosis levels of cells in each group were detected by flow cytometry;and the expression levels of miRNA126-regulated PI3K/AKT/mTOR pathway mRNAs and proteins were detected by qPCR and WB.Results Morphological observation after cell culture showed that more floating cells appeared in the model group compared with the sham-operated group,and the cell morphology of each dosing group improved compared with that of the model group,among which the medium-dose group of Shenshuaixiezhuo Decoction showed better performance;the proliferation activity of cells in the model group was significantly reduced(P<0.01)and the level of apoptosis was significantly increased(P<0.01)compared with that of the blank control group,and the level of proliferation and apoptosis in each dosing group improved compared with that of the model group;and the level of proliferation and apoptosis in each dosing group was improved compared with that of the model group.Compared with the model group,the expression of miRNA126 mRNA in the model group decreased significantly(P<0.05),and the expression levels of PI3K,AKT,and mTOR genes and proteins increased significantly(P<0.05);compared with the model group,the expression levels of miR-NA126 mRNA in the Cloxartan group,and the Shenshuaixiezhuo Decoction low,medium,and high dose groups increased significantly(P<0.05).Compared with the model group,miRNA126 mRNA expression increased significantly in the low,medium and high dose groups of chlorosartan group and Shenshuaixiezhuo Decoction group(P<0.05);PI3K,AKT,mTOR gene and phosphorylated protein expression levels decreased in all groups of Shenshuaixiezhuo Decoction(P<0.05),and autophagy-associated Bcelin1 protein expres-sion level increased(P<0.05).Conclusion Shenshuaixiezhuo Decoction may promote cellular autophagy pathway through miRNA126 regulation of PI3K/AKT/mTOR pathway,maintain aortic VEC cellular homeostasis,and play a role in protecting VEC and delaying ath-erosclerosis in chronic kidney disease combined with atherosclerosis.

Shenshuaixiezhuo DecoctionMicroRNA126Vascular endothelial cellsChronic kidney diseaseAtherosclero-sis

刘庚鑫、张格第、袁文萋、李福生、罗富里、晏子友

展开 >

江西中医药大学,江西南昌 330004

江西中医药大学附属医院,江西南昌 330000

肾衰泄浊汤 微小核糖核酸126 血管内皮细胞 慢性肾脏病 动脉粥样硬化

2024

时珍国医国药
时珍国医国药杂志社

时珍国医国药

北大核心
影响因子:0.887
ISSN:1008-0805
年,卷(期):2024.35(12)